Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel? - 09/12/20
Doi : 10.1016/j.accpm.2020.10.004
Philippe Montravers a, b, c, ⁎ 
, Elie Kantor a, Aurélie Gouel-Cheron a, d, e
, Elie Kantor a, Aurélie Gouel-Cheron a, d, e a Département d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, DMU PARABOL, HUPNVS, APHP, 75018 Paris France
b Université de Paris, 75018 Paris, France
c INSERM UMR 1152, Université de Paris,75000 Paris, France
d Institut Pasteur, Inserm UMR 1222, 75015 Paris, France
e National Institute of Allergy and Infectious Diseases, National Institutes of Health, Biostatistics Research Branch, Division of Clinical Research, Bethesda, MD, USA
⁎Corresponding author at: Département d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 46, Rue Henri-Huchard, 75018, Paris, France.Département d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard46, Rue Henri-HuchardParis75018France
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Keywords : SARS-CoV-2, COVID-19, anti-infective agents, anti-viral agent, antibiotic agent, anti-parasitic agent
El texto completo de este artículo está disponible en PDF.
Esquema
© 2020
Société française d'anesthésie et de réanimation (Sfar). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 39 - N° 6
P. 695-697 - décembre 2020 Regresar al número
Artículo precedente
- Artificial Intelligence for clinical decision support in Critical Care, required and accelerated by COVID-19
- Miia Jansson, Juanjo Rubio, Ricard Gavaldà, Jordi Rello
- COVID-19, steroids and other immunomodulators: The jigsaw is not complete
- Jordi Rello, Grant W. Waterer, Alexandre Bourdiol, Antoine Roquilly
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.